Keyword: Arcturus Therapeutics
Novartis' ex-oncology head jumps to startup; Axovant poaches Allergan's CMO; and Biogen brings on Pfizer dealmaker.
After settling a legal scuffle with its ex-CEO Joseph Payne and appointing four new board members, Arcturus reinstated Payne in his old role.
Arcturus Therapeutics and its ousted CEO Joseph Payne agreed to end litigation against each other.
Axovant CEO Hung resigned, Arcturus CSO and COO Chivukula stepped down, Celgene spinoff emerged with Bob Hariri at the reins.
Arcturus is losing its second executive in as many weeks: CSO/COO Pad Chivukula, who will take an advisory role.
Longtime Catalent CFO joins Allergan, Arcturus board and ousted CEO exchange fire, Lilly diabetes executive jumps to MannKind.
Arcturus Therapeutics VP Mark Herbert will take over as interim president after the ouster of Joseph Payne.
Johnson & Johnson has notched a deal with Arcturus Therapeutics to help with its new focus on hepatitis B.
The deal will give Arcturus a route to public investors at a time when interest in RNA drugs is flying high on the back of Alnylam’s phase 3 success.